Asia-Pacific accounted for a 45.3% share of global clinical trials activity in 2020, an increase of 6.4% compared with a 38.9% average over the last ten-years, according to GlobalData.
In Asia-Pacific, single country studies held a 91.3% share for all clinical trials in 2020, compared with the ten-year average of 88.4%. Multinational trials accounted for an 8.7% share in 2020 against an average of 11.6% in the last ten years.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials in Asia-Pacific
Industry sponsored trials held a 49.9% share of all the clinical trials in Asia-Pacific in 2020, a rise over their ten-year average of 43.1%. Non-industry sponsored trials accounted for a 50.1% share in 2020, down from an average of 56.9% in the last ten years.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
2020 industry sponsored clinical trials in Asia-Pacific – Top therapy areas
Oncology was the leading therapy area for industry sponsored clinical trials in Asia-Pacific in 2020 with a 28.8% share, up from its ten-year average of 24.5%.
Infectious Disease held an 18.8% share in 2020, up from its ten-year average of 12.4%.
In the third place was Central Nervous System with an 11.3% share in 2020, down from its ten-year average of 12.8%. Respiratory recorded an 8.9% share in 2020, a rise over its ten-year average of 5.9%.
With a share of 8.6% in 2020, Cardiovascular witnessed a drop over its ten-year average of 10.3%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored clinical trials in Asia-Pacific by top therapy areas
Oncology was the leading therapy area for non-industry sponsored clinical trials in Asia-Pacific in 2020 with a 28.4% share, up from a ten-year average of 26.4%.
In the second place was Infectious Disease with an 18.9% share in 2020, which represented a rise over a ten-year average of 9.2%.
With a share of 17.4% in 2020, Central Nervous System witnessed a drop over its ten-year average of 19.1%. Respiratory held a 9.1% share in 2020, up against a ten-year average of 4.5%.
Cardiovascular held an 8.1% share, which was down from ten-year average of 10.8%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
2020 clinical trials in Asia-Pacific by phase
In terms of phases, Phase I trials led the industry sponsored clinical trials in Asia-Pacific in 2020, with a share of 41.0%, marking a rise over a ten-year average of 26.5%.
Phase II trials stood next with a 29.1% share in 2020, which was down against a ten-year average of 29.8%.
In the third place was Phase III trials with a 16.7% share in 2020, down from its ten-year average of 26.3%.
Phase IV trials held a 13.2% share in 2020, with a 4.2% drop over its ten-year average of 17.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
For non-industry sponsored clinical trials in Asia-Pacific, Phase II trials held a leading share of 41.0% in 2020, down from its ten-year average of 58.4%.
In the second place was Phase I trials that held a 23.5% share in 2020 and saw a 15% rise over a ten-year average of 8.5%.
Phase IV trials stood at a 22.2% share, even against a ten-year average of 22.4%.
Phase III trials held a 13.3% share in 2020, up from its ten-year average of 10.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
